MDimune develops a smart drug delivery platform, BioDrone™, utilizing cell-derived vesicles to transport therapeutics directly to targeted areas within the body. This technology addresses the challenge of inefficient drug delivery, enhancing the efficacy of treatments for cancer and central nervous system disorders.
Funding
$8.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current drug delivery methods often lack precision, resulting in systemic exposure and limited efficacy, particularly in treating cancers and central nervous system disorders. This inefficiency necessitates higher drug dosages, leading to increased toxicity and reduced therapeutic benefits for patients.
Solution
MDimune has developed BioDrone™, a smart drug delivery platform based on cell-derived vesicles, designed to enhance targeted drug delivery within the body. This technology utilizes vesicles to transport therapeutic payloads directly to specific areas, improving treatment efficacy while minimizing off-target effects. By precisely delivering drugs to the intended site of action, BioDrone™ aims to reduce the required dosage, decrease systemic toxicity, and improve overall patient outcomes. The platform is applicable to a range of therapeutics, including gene therapies (mRNA, siRNA, miRNA), and is being developed for anti-cancer and central nervous system applications, including rare diseases.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions focused on developing targeted therapies for cancer, central nervous system disorders, and rare diseases.
Features
- Cell-derived vesicles for targeted drug delivery
- Customizable vesicle surface for enhanced targeting of specific tissues or cells
- Compatibility with various therapeutic payloads, including small molecules, proteins, and nucleic acids
- Scalable manufacturing process for producing clinical-grade BioDrone™ products
- Potential for improved drug efficacy and reduced systemic toxicity compared to conventional drug delivery methods
- Applications in oncology, neurology, and gene therapy